CLGN
Income statement / Annual
Last year (2024), CollPlant Biotechnologies Ltd.'s total revenue was $515,000.00,
a decrease of 95.30% from the previous year.
In 2024, CollPlant Biotechnologies Ltd.'s net income was -$16.61 M.
See CollPlant Biotechnologies Ltd.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$515,000.00 |
$10.96 M |
$299,000.00 |
$15.64 M |
$6.14 M |
$2.32 M |
$4.79 M |
$479,917.00 |
$75,911.00 |
$0.00 |
| Cost of Revenue |
$1.63 M
|
$1.99 M
|
$400,000.00
|
$2.01 M
|
$3.00 M
|
$1.88 M
|
$378,630.00
|
$14,961.00
|
$225,072.00
|
$202,819.00
|
| Gross Profit |
-$1.11 M
|
$8.97 M
|
-$101,000.00
|
$13.64 M
|
$3.14 M
|
$439,000.00
|
$4.41 M
|
$464,956.00
|
-$149,161.00
|
-$202,819.00
|
| Gross Profit Ratio |
-2.16
|
0.82
|
-0.34
|
0.87
|
0.51
|
0.19
|
0.92
|
0.97
|
-1.96
|
0
|
| Research and Development Expenses |
$10.52 M
|
$10.48 M
|
$10.26 M
|
$7.63 M
|
$4.07 M
|
$4.41 M
|
$5.16 M
|
$4.05 M
|
$4.36 M
|
$3.04 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$4.62 M
|
$3.62 M
|
$3.29 M
|
$2.38 M
|
$2.86 M
|
$1.77 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$48,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$5.63 M
|
$6.00 M
|
$6.74 M
|
$5.94 M
|
$4.67 M
|
$3.62 M
|
$3.29 M
|
$2.38 M
|
$2.86 M
|
$1.77 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$33,000.00
|
$21,507.00
|
$13,522.00
|
$9,878.85
|
$6,404.25
|
| Operating Expenses |
$16.14 M
|
$16.48 M
|
$17.00 M
|
$13.57 M
|
$8.73 M
|
$8.07 M
|
$8.48 M
|
$6.44 M
|
$7.24 M
|
$4.82 M
|
| Cost And Expenses |
$17.77 M
|
$18.47 M
|
$17.40 M
|
$15.58 M
|
$11.74 M
|
$9.95 M
|
$8.85 M
|
$6.45 M
|
$7.24 M
|
$4.82 M
|
| Interest Income |
$738,000.00
|
$788,000.00
|
$321,000.00
|
$219,000.00
|
$40,000.00
|
$10,000.00
|
$438,107.00
|
$72,793.00
|
$0.00
|
$0.00
|
| Interest Expense |
$17,000.00
|
$10,000.00
|
$34,000.00
|
$37,000.00
|
$34,000.00
|
$63,000.00
|
$15,134.00
|
$21,579.00
|
$33,482.14
|
$13,064.00
|
| Depreciation & Amortization |
$1.04 M
|
$1.10 M
|
$1.08 M
|
$773,000.00
|
$660,000.00
|
$539,000.00
|
$342,000.00
|
$291,633.00
|
$225,072.00
|
$201,861.00
|
| EBITDA |
-$16.21 M |
-$6.41 M |
-$16.02 M |
$838,000.00 |
-$4.94 M |
-$7.09 M |
-$3.90 M |
-$5.73 M |
-$6.95 M |
-$4.60 M |
| EBITDA Ratio |
-31.48
|
-0.58
|
-53.58
|
0.05
|
-0.8
|
-3.06
|
-0.82
|
-11.93
|
-91.53
|
0
|
| Operating Income Ratio |
-33.5
|
-0.69
|
-57.18
|
0
|
-0.91
|
-3.29
|
-0.85
|
-12.44
|
-94.33
|
0
|
| Total Other Income/Expenses Net |
$642,000.00
|
$493,000.00
|
$172,000.00
|
$172,000.00
|
-$175,000.00
|
-$3.53 M
|
-$2.00 M
|
-$94,000.00
|
-$101,993.84
|
$50,867.00
|
| Income Before Tax |
-$16.61 M
|
-$7.02 M
|
-$16.93 M
|
$237,000.00
|
-$5.77 M
|
-$11.16 M
|
-$3.69 M
|
-$6.01 M
|
-$7.25 M
|
-$4.78 M
|
| Income Before Tax Ratio |
-32.25
|
-0.64
|
-56.61
|
0.02
|
-0.94
|
-4.82
|
-0.77
|
-12.52
|
-95.52
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$172,000.00
|
-$172,000.00
|
$34,000.00
|
$3.53 M
|
$2.96 M
|
$28,442.00
|
-$86,281.19
|
$63,854.00
|
| Net Income |
-$16.61 M
|
-$7.02 M
|
-$16.75 M
|
$409,000.00
|
-$5.81 M
|
-$14.70 M
|
-$6.25 M
|
-$6.05 M
|
-$7.24 M
|
-$4.79 M
|
| Net Income Ratio |
-32.25
|
-0.64
|
-56.03
|
0.03
|
-0.95
|
-6.34
|
-1.31
|
-12.61
|
-95.37
|
0
|
| EPS |
-1.45 |
-0.62 |
-1.52 |
0.041 |
-0.84 |
-2.95 |
-1.43 |
-2.27 |
-3.6 |
-2.83 |
| EPS Diluted |
-1.45 |
-0.62 |
-1.52 |
0.0342 |
-0.84 |
-2.95 |
-1.43 |
-2.27 |
-3.6 |
-2.83 |
| Weighted Average Shares Out |
$11.45 M
|
$11.39 M
|
$11.03 M
|
$9.97 M
|
$6.89 M
|
$4.99 M
|
$4.38 M
|
$2.66 M
|
$2.01 M
|
$1.69 M
|
| Weighted Average Shares Out Diluted |
$11.45 M
|
$11.39 M
|
$11.03 M
|
$11.97 M
|
$6.89 M
|
$4.99 M
|
$4.38 M
|
$2.66 M
|
$2.01 M
|
$1.69 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
